Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Non-randomized Study of the Efficacy of Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

NCT03850730 is registered in ClinicalTrials.gov with Cure HHT as lead sponsor.

NCT NCT03850730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03850730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Non-randomized Study of the Efficacy of Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Lead sponsor
Cure HHT
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 1, 2023
Completion date
December 31, 2025
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

epistaxis, hereditary hemorrhagic telangiectasia